Skip to main content
Premium Trial:

Request an Annual Quote

HealthŌme, GalenusRx Partner on Precision Medicine Safety Program

NEW YORK – Genomics-based health management company HealthŌme said Wednesday that it has partnered with medication safety organization GalenusRx to reduce the incidence of adverse drug effects among its policyholders through pharmacogenomics and precision medicine consultation.

Huntsville, Alabama-based HealthŌme will combine its disease management expertise and pharmacogenomics (PGx) testing capabilities with GalenusRx's Actionable PolyPharmacy Risk Index for Safety and Equity (APPRAISE) platform, which analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to provide pharmaceutical risk assessments.

Through its omics-based CancerŌme health management program, HealthŌme provides policyholders with hereditary cancer risk screening and PGx testing. GalenusRx will use that PGx information to make personalized medication plan recommendations. Policyholders also receive on-demand consultations from a precision clinical pharmacist, who can communicate any recommended medication adjustments to the policyholder's prescribing physician.

For policyholders that are diagnosed with cancer, CancerŌme further provides a comprehensive, end-to-end solution that incorporates additional genomic testing, oncology nurse navigator services, and medication management support.

Financial details of the partnership were not disclosed.